TVTX - Travere Therapeutics

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Travere Therapeutics Non-GAAP EPS of $2.27 beats by $2.23, revenue of $37.09M
• Travere Therapeutics Q3 2023 Earnings Preview
• Travere stock climbs 6% amid two medical meeting presentations
• William Blair downgrades Travere, cites commercial risk for Filspari
• Wells Fargo lowers rating, price target for Travere Therapeutics
• Travere falls after Phase 3 data for kidney disease candidate
• Travere Therapeutics GAAP EPS of -$1.13 beats by $0.03, revenue of $57M beats by $3.4M
• Travere Therapeutics Q2 2023 Earnings Preview
• JP Morgan starts Travere at overweight, sees shares as undervalued
• Travere gains 10% on data for metabolic disorder therapy
• Travere Therapeutics Non-GAAP EPS of -$0.82 beats by $0.25, revenue of $57M beats by $6.4M
• Travere Therapeutics Q1 2023 Earnings Preview
• Travere sinks after Phase 3 trial setback for kidney disease therapy
• Travere prices stock and warrants offering
• Travere Therapeutics a buy at Guggenheim on long-term potential of Filspari
• Travere Therapeutics launches $175M stock offering
• Travere Therapeutics Non-GAAP EPS of -$0.76 beats by $0.08, revenue of $55.9M beats by $2.88M
• Travere Therapeutics Q4 2022 Earnings Preview
• Travere Filspari gets FDA accelerated approval for reducing proteinuria in kidney disease patients
• Travere Therapeutics expects FY22 revenue to be in line with consensus